Investigation of the Relationship Between MTHFR C677T Gene Variation and Serum Copper Levels in Patients Diagnosed with Parkinson's

Parkinson Tanısı Almış Hastalarda MTHFR C677T Gen Varyasyonu ve Serum Bakır Düzeyleri Arasındaki İlişkinin Araştırılması

Arzu Ay¹, Nevra Alkanli ², Sibel Guler³

¹Department of Biophysics, Faculty of Medicine, Trakya University, Edirne, Turkey
²Department of Biophysics, Faculty of Medicine, Haliç University, Istanbul, Turkey
³Department of Neurology, Faculty of Medicine, Trakya University, Edirne, Turkey

Abstract

Objective: In this study, we aimed to investigate the relationship between MTHFR C677T gene variation and serum copper levels in patients diagnosed with Parkinson's.

Materials and Methods: For our study, patient and control groups were formed including 63 Parkinson's patients and 32 healthy controls. Genotype distributions for MTHFR gene variation were determined and serum copper levels were measured. In these processes PCR, RFLP and atomic absorption spectrophotometry methods were applied.

Results: Serum Cu levels of Parkinson's patients were found to be significantly higher than healthy controls. Although the significant difference was not found between the patient and control groups in terms of genotype distributions of the MTHFR C677T gene variation, CC homozygote genotype of this gene variation was observed significantly more than other genotypes in the patient group. In addition, the C allele frequency of this gene variation was determined significantly different from the Hardy-Weinberg distribution in Parkinson's patients. Serum copper levels of Parkinson's patients carrying CT and TT genotypes were detected significantly higher than the serum copper levels of controls carrying the same genotypes.

Conclusion: In our study, in Thrace population, it was determined that the relationship between MTHFR C677T gene variation and serum copper levels may be an important factor for Parkinson's disease. In conclusion, the evaluation of MTHFR C677T gene variation genotype distributions and serum copper levels together is extremely important for prognosis of Parkinson's disease.

Keywords: Parkinson disease; methylenetetrahydrofolate reductase (NADPH2); polymorphism; genetic; copper; polymerase chain reaction.

Introduction

Parkinson's disease is the second most common neurodegenerative disorder after Alzheimer's disease (1). Parkinson's disease develops as a result of progressive degeneration and loss of dopaminergic neurons in the substantia nigra in the midbrain and is characterized by tremors, bradykinesia, impaired postural reflexes, alpha-synuclein protein aggregation. Although the

*Corresponding Author: Arzu Ay ¹Department of Biophysics, Faculty of Medicine, Trakya University, Edirne, Turkey
E-mail: arzuytrakya.edu.tr Orcid: Arzu Ay 0000-0002-8412-091X, Nevra Alkanli 0000-0002-3745-8838, Sibel Guler 0000-0001-6375-6153

Received:10.10.2021, Accepted:04.04.2022
etiology of Parkinson’s disease has not been fully explained, genetic and environmental factors are effective in the pathogenesis of the disease (2-4). Folate plays an important role in the nervous system and brain development. Abnormal DNA methylation develops as a result of chronic folate / methyl deficiency (5-9). Methyleneetetrahydrofolate reductase (MTHFR) is an important enzyme that is effective in folate metabolism pathways, so MTHFR gene has been associated with Parkinson’s disease susceptibility. MTHFR gene is localised on chromosome 1p36.3 (10). The MTHFR C677T gene variation is characterized by cytosine / thymine base substitution and alanine / valine amino acid change in the N-terminal catalytic region of the MTHFR gene (4,11,12). MTHFR enzyme activity decreases as a result of this genetic variation (13,14). Imbalances in trace element homeostasis, which is known as an important environmental factor in Parkinson’s pathogenesis, play an important role in neurodegeneration associated with Parkinson’s disease. Abnormal levels of some trace elements may adversely affect the nervous system through induction of the production of reactive oxygen species (15). Cu is an essential cofactor for the antioxidant function of ceruloplasmin and the enzymatic activity of superoxide dismutase (16). It has been suggested that oxidative stress may be an important cause of neuronal death and the development of oxidative stress may be associated with an imbalance in Cu homeostasis. Decreased ceruloplasmin levels in Parkinson’s patients demonstrate this (1). Cu plays a dual role in Parkinson's disease. Cu has been associated with increase in oxidative stress, the formation of Lewy bodies through alpha-synuclein protein oligomerization (17). Therefore, in our study, we aimed to investigate the role of correlation between MTHFR C677T gene variation and serum Cu levels in Parkinson’s patients.

Materials and Methods

Patients and control subjects: Trakya University Faculty of Medicine Non-Invasive Clinical Research Ethics Committee was applied. The approval of ethics committee was obtained from the komite for our study (Protocol code: TÜTF-BAEK 2017/77). Signed informed consent forms were obtained from these groups. Peripheral venous blood was obtained from Trakya University Faculty of Medicine Neurology Department for our study. Experimental parts of the study were carried out in Trakya University Faculty of Medicine Department of Biophysics. This study consisted of 63 Parkinson's patients and 32 controls. The patient group in our study includes patients diagnosed Parkinson’s disease. The patients applied to Trakya University Faculty of Medicine Neurology Outpatient Clinics were diagnosed with Parkinson's disease due to the presence of clinical symptoms such as rigidity, asymmetric tremor, and postural instability as a result of a comprehensive neurological and physical examination. Patients and controls that are younger than 19 years and those have a history of malignancy were excluded from our study. Pregnant and breastfeeding women, individuals with any other neurodegenerative diseases associated with central nervous system were excluded from this study. In addition, people who took trace element supplements were also excluded from our study. Peripheral venous blood containing ethylenediaminetetraacetic acid (EDTA) was used to determine MTHFR C677T gene variation genotype distributions, while peripheral venous blood without EDTA was used to determine serum Cu levels.

DNA isolation and PCR-RFLP methods: DNA isolation was performed from peripheral blood samples of patients and controls. These blood samples contained EDTA. DNA blood isolation kits (Invitrogen / Thermo Fisher Scientific, USA) were used for DNA isolation. Polymerase chain reaction (PCR) (Techne TC-3000 G, USA) and restriction fragment length polymorphism (RFLP) methods were used to determine the MTHFR C677T gene variation genotype distributions (12) (Table 1). For the PCR method, 25 µl of PCR mixture was prepared and these PCR reaction products were used for the RFLP method. PCR product lengths (198bp) for the MTHFR C677T gene variation were observed in 2% agarose gel electrophoresis (Cleaver Scientific for electrophoresis tank and EC-105, Cleaver Scientific MP300 V for power source, United Kingdom) (Figure 1). The genotype distributions of MTHFR C677T gene variation were observed in 2% agarose gel electrophoresis (Cleaver Scientific for electrophoresis tank and EC-105, Cleaver Scientific MP300 V for power source, United Kingdom). CC homozygous genotype (198bp), CT heterozygous genotype (198bp, 175bp, 23bp) and TT homozygous genotype (175bp, 23bp) were observed for the MTHFR C677T gene variation (Figure 2).
**Table 1:** Primer series, PCR condition, restriction enzyme and product lengths for MTHFR C677T gene variation

| Gene Variations | Primer series | PCR Conditions             | RE       |
|-----------------|---------------|----------------------------|----------|
| MTHFR (C677T)   | FP:5’-TGAAGGAGAAGGTGTCTGCGGGA-3’ | 5 minutes at 94°C<br>30 seconds at 94°C<br>30 seconds at 62°C<br>5 minutes at 72°C | HinfI    |
|                 | RP:5’-AGGACGGTGCGGTGAGAGTG-3’     | 30 cycle                       |          |

Gene Variation | PCR Product Length | Genotype Distributions | Product Lengths

- MTHFR C677T<br>CC 198bp<br>CT 198bp, 175bp, 23bp<br>TT 175bp, 23bp

(23bp is not observed; 50bp marker)

**FP:** Forward primer; **RP:** Reverse primer; **PCR:** Polymerase chain reaction; **RE:** Restriction enzyme

**Figure 1.** PCR samples of patient and control groups for MTHFR C677T gene variation.

**Figure 2.** RFLP samples of patient and control groups for MTHFR C677T gene variation.

*CC genotype in MTHFR C677T gene polymorphism (198 bp; Lanes 2, 6, 7, 9, 11 and 12), TT genotype (175 bp, 23 bp; Lane 3 numbered band) and CT genotype (198 bp, 175 bp, 23 bp; Lanes 1, 4, 5, 8, 10, 13 and 14)*

*Note: 23 bp not observed; 50 bp marker.*
**Determination of serum Cu levels:** EDTA-free peripheral venous blood samples of Parkinson's patients and healthy controls were centrifuged at 5000 rpm for 5 minutes. Serum samples were separated from centrifuged blood samples. Distilled water was added to these serum samples and the total volume was prepared as 5 milliliters. This mixture was homogenized. Standard solutions (0.5, 1.0, 1.5, 2.0, 2.5 ppm) were prepared for serum Cu measurement. Serum Cu levels were measured by atomic absorption spectrophotometer method. Concentration-calibration curve was drawn for element Cu using standard solutions (18).

**Statistical analyses:** For MTHFR C677T gene variation, the relationships between genotypes and groups were determined by Chi-square test. Odds ratio and 95% confidence interval values are calculated as a result of logistic regression analysis for MTHFR C677T gene variation genotype distributions between patient and control groups. In addition, the conformity of allele frequencies of the MTHFR C677T gene variation to the Hardy-Weinberg distribution was analyzed. Serum Cu levels were compared between Parkinson's patients and controls by Mann-Whitney U test. Independent-Samples Kruskal-Wallis test was used to determine serum Cu levels according to MTHFR C677T gene variation genotype distributions between Parkinson's patient group and control group. In our study, the results were expressed as mean ± standard deviation. Statistical significance level was considered as 5% and SPSS (Statistics Package of Social Science, V: 20) for windows was used for all statistical analyses.

**Results**

In our study CC, CT, TT genotypes of MTHFR gene variation were observed more in Parkinson's patients than in healthy controls. MTHFR C677T gene variation genotype distributions did not show a significant difference between the patient and control groups (p>0.05). However CC homozygote genotype of this gene variation was observed significantly more than other genotypes in the patient group (p<0.05). In addition, C allele frequency of the MTHFR C677T gene variation was found to be significantly different from the Hardy-Weinberg distribution in Parkinson's patients (p<0.05) (Table 2). Serum Cu levels were detected significantly higher in Parkinson patients than controls (Table 3). The significant difference was determined between the patient and control groups in terms of serum Cu levels (p<0.05). In Parkinson's patients carrying TT genotype, serum Cu levels were detected higher than those carrying CT and CC genotypes. Serum Cu levels of Parkinson's patients carrying CT and TT genotypes were detected significantly higher than controls carrying the same genotypes (p<0.05) (Table 4).

**Discussion**

Parkinson's disease is a neurodegenerative disease and may eventually affect the quality of life of patients. Parkinson's disease is known as a multifactorial disease stem from a combination of genetic factors and environmental factors (19). Many genetic variations have been identified in the MTHFR gene and especially two of these genetic variations may affect the MTHFR enzymatic activity. In a meta-analysis study, in Caucasian population, TT and CT genotypes have been associated with higher risk of Parkinson's disease compared to CC homozygous genotype (3). In another meta-analysis study, in Asian population, T allele of the MTHFR C677T gene variation was detected as genetic risk factor in Parkinson's disease (20). In another study, MTHFR C677T gene variation has been associated with a reduced risk of Parkinson's disease (21). In a study, MTHFR C677T gene variation has been associated with increased susceptibility for Parkinson's disease (22). In our study, CC, CT and TT genotypes of MTHFR C677T gene variation were observed more in Parkinson's patient group than in healthy control group. MTHFR C677T gene variation genotype distributions did not show a significant difference between the patient and control groups (p>0.05). However CC homozygote genotype of this gene variation was observed significantly more than other genotypes in the patient group (p<0.05). In addition, the C allele frequency of the MTHFR C677T gene variation was determined significantly different from the Hardy-Weinberg distribution in Parkinson's patients (p<0.05) Imbalance in some trace element levels may adversely affect the central nervous system. Oxidative stress can develop as a result of abnormalities in these trace element levels and oxidative stress may be an important environmental risk factor in the pathogenesis of Parkinson's disease (17). Trace elements have important roles in the pathogenesis of Parkinson’s disease and neurotoxic effects of trace elements such as Cu have been reported. In Parkinson's disease, Cu ions bind less to ceruloplasmin and free Cu ions can coordinate with low molecular weight ligands. Free or active
Table 2. Comparison of genotype distributions between patient group and healthy control group

| Genotype distributions | Patient group=63 (%) | Control group=32 (%) | p |
|------------------------|----------------------|----------------------|---|
| MTHFR C677T            |                      |                      |   |
| CC                     | 30 (71.4%)           | 12 (28.6%)           | 0.572a |
| CT                     | 21 (60.0%)           | 14 (40.0%)           |   |
| TT                     | 12 (66.7%)           | 6 (33.3%)            |   |

Genotype distributions: Patient group (n=63) and Control group (n=32) p

| MTHFR C677T | Patient group (n=63) | Control group (n=32) |
|-------------|----------------------|----------------------|
| CC          |                      |                      |
| CT          |                      |                      |
| TT          |                      |                      |

Genotype distributions: Patient group (n=63)

| MTHFR C677T | | p |
|-------------||---|
| CC          | | |
| CT          | | |
| TT          | | |

Gene Variations

| Allele | Case | Frequency |
|--------|------|-----------|
| C      | 81   | 0.64286   |
| T      | 45   | 0.35714   |

MTHFR C677T

Hardy-Weinberg Equilibrium Test: Pearson chi2 = 4.73235
Pr= 0.0296 a

Hardy-Weinberg Equilibrium Test: Pearson chi2 = 0.27747
Pr= 0.5984 b

*Chi-square test; aHardy-Weinberg Equilibrium test; *: Significance (p<0.05) CC: Cytosine–Cytosine; CT: Cytosine–Thymine; TT: Thymine–Thymine

Table 3. Comparison of copper levels between patient and control groups

| Trace element | Groups Patient (Mean ± SD) (n=63) | Control (Mean ± SD) (n=32) | p |
|---------------|-----------------------------------|-----------------------------|---|
| Cu (µg/dl)    | 180.30 ± 6.467                    | 143.69 ± 4.862              | 0.001a |

*aMann Whitney U test, *: Significance (p<0.05) Cu: Copper

Table 4. Cu levels according to C677T gene variation genotype distributions

| MTHFR C677T Gene Variation | Genotypes | Trace elements | Parkinson group n (Mean ± SD) | Control group n (Mean ± SD) | p |
|-----------------------------|-----------|----------------|-----------------------------|-----------------------------|---|
| CC                          | Cu (µg/dl)| 30 (150.33 ± 19.149) | 12 (147.42 ± 26.983) | >0.05a |
| CT                          | Cu (µg/dl)| 21 (198.71 ± 63.728) | 14 (141.71 ± 31.267) | 0.001a* |
| TT                          | Cu (µg/dl)| 12 (222.50 ± 38.668) | 6 (140.83 ± 22.203) | 0.001a* |

*Independent-Samples Kruskal-Wallis test, *: Significance (p<0.05) CC: Cytosine-Cytosine; CT: Cytosine-Thymine; TT: Thymine-Thymine; Cu: Copper

copper ions contribute to neurodegeneration by showing redox activities and thus play a pathogenic role. Cu-induced oxidative stress has been associated with the activation of transcription factors that regulate neuroinflammatory reactions. Progression of free Cu accumulation tendency may be associated with significantly increased Cu neurotoxicity in Parkinson’s patients (19). The main component of Lewy bodies is alpha-synuclein, and alpha-synuclein binds to the Cu ion in the oxidation states of Cu. Aggregate formation and oxidative...
stress may occur as a result of this binding. Imbalance in Cu homeostasis has been associated with protein aggregation and development of oxidative stress (1). In some studies, significantly increased Cu levels were detected in the substantia nigra and cerebrospinal fluids of Parkinson's patients (23,24). In another study, serum Cu levels were found to be significantly higher in patients with severe Parkinson's than in healthy controls (25). In a study performed with Spanish population, increased serum Cu concentrations were determined in the cerebrospinal fluids of Parkinson's patients (16). In a study performed with the Russian population, decreased serum Cu concentrations were detected in Parkinson's patients (1). The differences in these results may be due to the variability in the clinical parameters of Parkinson's disease, different demographic parameters, different lifestyle and environmental conditions, and different selection criteria for the patient and control groups (19). In our study, serum Cu levels were determined significantly higher in Parkinson's patients compared to controls. The significant difference was detected between these groups in terms of serum copper levels (p<0.05). In our study, in Parkinson's patients carrying TT genotype, serum copper levels were observed higher than carrying CC and CT genotypes. Also, in Parkinson's patients carrying CT and TT genotypes, serum copper levels were determined significantly higher than controls carrying the same genotypes (p<0.05). Consequently, in our study, serum copper levels according to MTHFR C677T gene variation genotype distributions may be evaluated as risk factor for Parkinson's disease.

Conclusion

In our study, MTHFR C677T gene variation and serum Cu levels were evaluated together in the Parkinson's patients. It is thought that the obtaining of some biomarkers in our study may be important in the early diagnosis, prognosis and progression of Parkinson's disease. Serum Cu homeostasis may be impaired and Cu trace element activity and metabolism may be affected as a result of MTHFR C677T gene variation. As a result, it is thought that it may contribute to neurodegeneration due to oxidative stress. It is thought that the different results obtained in studies performed with different populations may be due to different selection criteria for patient and control groups, lifestyle differences, genetic variability, and sample size. In our study, in Thrace population, it was determined that the relationship between MTHFR C677T gene variation and serum copper levels may be an important factor for Parkinson's disease. The evaluation of genetic factors such as genetic variations that may be effective in the pathogenesis of Parkinson's disease and environmental factors such as trace elements together and obtaining biomarkers are very important in terms of developing new therapeutic strategies and drugs related to Parkinson's disease.

Acknowledgements: Our study was carried out in departments of Biophysics, Neurology in Trakya University Faculty of Medicine. For statistical analysis, we would like to thanks to Prof. Dr. Necdet SUT in Trakya University Faculty of Medicine, Head of the Department of Biostatistics and Medical Informatics.

Compliance with Ethical Standards

Ethical approval: For our study, ethics committee approval was obtained with TÜTF-BAEK 2017/77 protocol code from Trakya University Faculty of Medicine Non-Invasive Clinical Research Ethics Committee.

Author Contribution: 1.Concept: NA, AA; 2. Design: NA, AA; 3. Control: NA, AA; 4. Materials; 5. AA, SG; 6. Data Collection and Processing: NA, AA; 7. Analysis and Interpretation: NA, AA; 8. Literature Review: NA, AA; 9. Writing-Original Draft: NA, AA; 10. Writing Review and Revision: NA, AA; 11. Critical Review: NA, AA; 12. Software and Visualization: NA, AA.

Consent to Participate: A signed informed consent form was obtained from each of the individuals with Parkinson's disease and the control group.

Conflict of Interest: The authors declare that they have no conflict of interest.

Financial Disclosure: This study was not financially supported.

References

1. Karpenko MN, Ilyicheva EY, Muruzheva ZM, Milyukhina IV, Orlov YA, Puchkova LV. Role of Copper Dyshomeostasis in the Pathogenesis of Parkinson's Disease. Bull Exp Biol Med 2018;164(5):596-600.
2. Simon DK, Tanner CM, Brundin P. Parkinson Disease Epidemiology, Pathology, Genetics, and Pathophysiology. Clin Geriatr Med 2020;36(1):1-12.
3. Liu L, Zhang L, Guo L, Yu Q, Li H, Teng J, et al. MTHFR C677T and A1298C polymorphisms may contribute to the risk
of Parkinson's disease: A meta-analysis of 19 studies. Neurosci Lett 2018;662:339-345.
4. Diao HM, Song ZF, Xu HD. Association Between MTHFR Genetic Polymorphism and Parkinson's Disease Susceptibility: A Meta-analysis. Open Med (Wars) 2019;14:613-624.
5. McGeer PL, Itagaki S, Boyes BE, McGeer EG. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 1988;38(8):1285-1291.
6. Yamagata K, Andreasen KI, Kaufmann WE, Barnes CA, Worley PF. Expression of a mitogen-inducible cyclooxygenase in brain neurons: regulation by synaptic activity and glucocorticoids. Neuron 1993;11(2):371-386.
7. Beiche F, Klein T, Nüsing R, Neuhuber W, Goppelt-Struebe M. Localization of cyclooxygenase-2 and prostaglandin E2 receptor EP3 in the rat lumbar spinal cord. J Neuroimmunol 1998;89(1-2):26-34.
8. Chandrasekharan NV, Dai H, Roos KL, Evanson NK, Tomsk J, Elton TS, et al. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci U S A 2002;99(21):13926-13931.
9. Warner TD, Mitchell JA. Cyclooxygenase-3 (COX-3): filling in the gaps toward a COX continuum? Proc Natl Acad Sci U S A 2002;99(21):13371-13373.
10. Smith WL, DeWitt DL, Garavito RM. Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem 2000;69:145-182.
11. Chan PH. Role of oxidants in ischemic brain damage. Stroke 1996;27:1124-1129.
12. Alkanli N, Sipahi T, Ay A, Guldenke B, Bakir A, Alkanli SS, et al. Calcitonin related polypeptide alpha gene polymorphisms according to plasma total homocysteine levels in ischemic stroke patients of Trakya Region. Biotechnol Biotechnol Equip 2018;32(5):1257-1265.
13. Adani G, Filippini T, Michalke B, Vinceti M. Selenium and Other Trace Elements in the Etiology of Parkinson's Disease: A Systematic Review and Meta-Analysis of Case-Control Studies. Neuroepidemiology 2020;54(1):1-23.
14. Jiménez-Jiménez FJ, Fernández-Calle P, Martínez-Vanaclocha M, Herrero E, Molina JA, Vázquez A, et al. Serum levels of zinc and copper in patients with Parkinson's disease. J Neurol Sci 1992;112(1-2):30-33.
15. Ganguan MK, Batra J, Kushwaha S, Agarwal R. Role of Iron and Copper in the Pathogenesis of Parkinson's Disease. Indian J Clin Biochem 2017;32(3):353-356.
16. Ay A, Gulysar T, Alkanli N, Sipahi T, Cicin I, Kocak Z, et al. Investigation of the relationship between GSTM1 gene variations and serum trace elements, plasma malondialdehyde levels in patients with colorectal cancer. Mol Biol Rep 2021;48(10):6911-6921.
17. Alkanli N, Sipahi T, Ay A, Guldiken B, Bakir A, Alkanli SS, et al. Calcitonin related polypeptide alpha gene polymorphisms according to plasma total homocysteine levels in ischemic stroke patients of Trakya Region. Biotechnol Biotechnol Equip 2018;32(5):1257-1265.
18. Adani G, Filippini T, Michalke B, Vinceti M. Selenium and Other Trace Elements in the Etiology of Parkinson's Disease: A Systematic Review and Meta-Analysis of Case-Control Studies. Neuroepidemiology 2020;54(1):1-23.
19. Jiménez-Jiménez FJ, Fernández-Calle P, Martínez-Vanaclocha M, Herrero E, Molina JA, Vázquez A, et al. Serum levels of zinc and copper in patients with Parkinson's disease. J Neurol Sci 1992;112(1-2):30-33.
neurodegenerative diseases (Alzheimer’s, Parkinson’s and prion diseases), Coord. Chem Rev 2012;256:2129–2141.

25. Hegde ML, Shanmugavelu P, Vengamma B, Rao TS, Menon RB, Rao RV, et al. Serum trace element levels and the complexity of inter-element relations in patients with Parkinson’s disease. JTEMB 2004;18:163-171.